MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Epigenome-wide and gene-targeted epigenetic profile of isolated REM Sleep Behaviour Disorder: a clinico-molecular study

    L. Baldelli, C. Pirazzini, L. Sambati, F. Ravaioli, F. Di Laudo, D. Gentilini, P. Guaraldi, C. Franceschi, P. Cortelli, P. Garagnani, G. Calandra-Buonaura, MG. Bacalini, F. Provini (Bologna, Italy)

    Objective: Comprehensively characterize the epigenetic profile of isolated REM Sleep Behaviour Disorder (iRBD) using genome-wide and gene-targeted approaches, linking it to clinical measures and  phenoconversion.…
  • 2025 International Congress

    Facial Blendshape Index(FBI) for Quantification of Hypomimia on Parkinson´s Disease

    B. Koyak, T. Menzel, M. Botsch, A. Spottke, M. Reuter, U. Wüllner, NA. Aziz (Dortmund, Germany)

    Objective: To evaluate the validity of ExpressionTracker, an app generating personalized facial blendshapes, for objective quantification of hypomimia in patients with Parkinson’s disease (PD) [1].…
  • 2025 International Congress

    Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

    T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)

    Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…
  • 2025 International Congress

    Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana

    YAW. Osei, SF. Sarfo, FAY. Yeboah Agyemang (Kumasi, Ghana)

    Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…
  • 2025 International Congress

    Cognitive Improvement in Parkinson’s Disease Patients After Intravenous Mesenchymal Stem Cell Infusion: Results from a Phase 2 Randomized Trial

    T. Thomas, J. Martinez-Lemus, E. Tharp, C. Green, C. Onuigbo, J. Suescun, T. Le, E. Rodarte Rascon, R. Ritter Iii, T. Ellmore, M. Schiess (Houston, USA)

    Objective: Assess the impact of treatment with intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) on cognition in patients with mild-moderate Parkinson’s Disease (PD).…
  • 2025 International Congress

    Modified Delphi consensus approach to develop recommendations for diagnosis, evaluation and management of cognitive disorders in Parkinson’s disease

    D. Pourzinal, D. Brooks, D. Sriram, L. Mitchell, N. Pachana, K. Shrubsole, B. Wood, J. O'Sullivan, R. Marsh, A. Lehn, J. Liddle, E. Tan, WK. Halford, N. Page, N. Dissanayaka (HERSTON, Australia)

    Objective: We aimed to develop harmonised recommendations for the diagnosis, evaluation and management of cognitive disorders in PD using a modified Delphi process. Background: Differences…
  • 2025 International Congress

    Telephone-Based Cognitive Screening for MCI to Dementia in Parkinson’s Disease

    R. Ferrucci, A. de Sandi, F. Verardo, D. Mellace, A. Marfoli, S. Zago, E. Mailland, G. Pravettoni, F. Mameli, F. Ruggiero, E. Zirone, S. Marceglia, A. Priori, F. Cogiamanian, M. Vergari, C. Manzoni, E. Aiello (Milan, Italy)

    Objective: The aim of this study is to evaluate whether telephone-based cognitive screening could be an effective and sustainable alternative to traditional in-person neuropsychological assessment.…
  • 2025 International Congress

    Longitudinal Analysis of Cognitive Changes in Parkinson’s Disease Subjects at Risk of Developing Probable REM Sleep Behavior Disorder (RBD)

    A. Basu, J. Ruiz Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

    Objective: To characterize the cognitive profile of Parkinson’s Disease (PD) patients that develop probable REM sleep behavior disorder (pRBD) within 8 years after PD diagnosis…
  • 2025 International Congress

    Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy

    K. Ikenaka, K. Kakuda, Y. Kimura, H. Mochizuki (Suita, Japan)

    Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…
  • 2025 International Congress

    Subthalamic Deep Brain Stimulation Modulates Cognitive-Motor Integration in Parkinson’s Disease: Insights from a Dual-task fNIRS Study

    YQ. Zhang, JP. Li, Y. Liang (Beijing, China)

    Objective: To investigate the effects of STN-DBS on cognitive-motor dual-task performance in PD patients using an executive function-motor function dual-task paradigm combined with functional near-infrared…
  • « Previous Page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley